Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Anika Therapeutics (ANIK) Consolidated Net Income: 2010-2025

Historic Consolidated Net Income for Anika Therapeutics (ANIK) over the last 15 years, with Sep 2025 value amounting to $846,000.

  • Anika Therapeutics' Consolidated Net Income rose 103.01% to $846,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$18.8 million, marking a year-over-year decrease of 56.50%. This contributed to the annual value of -$47.6 million for FY2024, which is 39.97% up from last year.
  • Anika Therapeutics' Consolidated Net Income amounted to $846,000 in Q3 2025, which was up 24.96% from $677,000 recorded in Q2 2025.
  • Anika Therapeutics' 5-year Consolidated Net Income high stood at $16.2 million for Q4 2023, and its period low was -$28.1 million during Q3 2024.
  • In the last 3 years, Anika Therapeutics' Consolidated Net Income had a median value of -$2.6 million in 2024 and averaged -$4.6 million.
  • Data for Anika Therapeutics' Consolidated Net Income shows a peak YoY increase of 411.38% (in 2022) and a maximum YoY decrease of 853.99% (in 2022) over the last 5 years.
  • Anika Therapeutics' Consolidated Net Income (Quarterly) stood at -$3.2 million in 2021, then surged by 411.38% to $10.1 million in 2022, then spiked by 60.71% to $16.2 million in 2023, then slumped by 219.74% to -$19.4 million in 2024, then surged by 103.01% to $846,000 in 2025.
  • Its Consolidated Net Income was $846,000 in Q3 2025, compared to $677,000 in Q2 2025 and -$915,000 in Q1 2025.